Regulators’ concerns over the unfettered sale of CBD have burst into the open with the US Food and Drug Administration (FDA) issuing an interim warning on the potential harmful effects of CBD.
At the same time, the FDA announced it had sent warning letters (again) to a further 15 companies, stating that they should not be making medical claims on the health benefits of CBD and gave them 15 working days to deal with the issue.
The FDA announcements sent shivers through the markets hitting the share prices of companies invested in the CBD space. Whilst it says it is still seeking to answer questions about the ‘science, safety, and quality of products containing CBD’ it pulled no punches.
In what it described as a ‘Consumer Update’ it says: “The FDA is concerned that people may mistakenly believe that trying CBD can’t hurt. The agency wants to be clear that we have…